[Skip to Content]
[Skip to Content Landing]
April 4, 2012

The Challenge of Individualizing Treatments for Patients With Breast Cancer

Author Affiliations

Author Affiliations: Departments of Medicine and Health Management & Policy, University of Michigan, Ann Arbor (Dr Katz); and Department of Clinical Oncology, Memorial Sloan-Kettering Cancer Center, and Weill Medical College of Cornell University (Dr Morrow), New York, New York.

JAMA. 2012;307(13):1379-1380. doi:10.1001/jama.2012.409

One of the most complex challenges clinicians and their patients with breast cancer face is to determine a treatment plan for disease with relatively favorable prognosis. Advances in treatment have improved life expectancy, but these advances have come at a steep price because treatments impose substantial morbidity and burden on patients and their families. Concerns about the potential harm of treatments have increased as population-based screening has identified an increased number of breast cancer patients with relatively favorable prognosis.1 These concerns have motivated several initiatives to reduce morbidity and treatment burden.

First Page Preview View Large
First page PDF preview
First page PDF preview